← Back to all trials
Not Yet Recruiting
NCT07654426
The CARDIOPROTECT Trial
Conditions: Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 60
Sponsor: Beth Israel Deaconess Medical Center
Location: Beth Israel Deaconess Medical Center Boston Massachusetts
Summary
This trial is to evaluate if dexrazoxane is safer and more effective than liposomal doxorubicin in preventing heart failure events in participants with diffuse large B-cell lymphoma (DLBCL) undergoing either standard of care R-CHOP or pola-R-CHP treatment regiments.
The names of the study drugs involved in this study are:
* Dexrazoxane (a type of Topoisomerase II Inhibitor)
* Liposomal Doxorubicin (a type of Topoisomerase II Inhibitor)
* Standard of care R-CHOP treatment regimen (Cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab)
* Standard of care pola-R-CHP treatment regimen: Cyclophosphamide, doxorubicin, polatuzumab vedotin-piiq, prednisone, rituximab
Eligibility Criteria
Inclusion Criteria:
* Participants must have histologically confirmed diffuse large B-cell lymphoma, histologically transformed large B cell lymphoma from a prior indolent lymphoma, or other high-grade B-cell lymphoma for which R-CHOP or pola-R-CHP are planned. Any cancer stage is permitted.
* Participants must not have received any prior chemotherapy for this malignancy. Pre-phase steroids are allowed. Prior treatment for a different malignancy is allowed, including prior treatment for indolent lymphoma.
* Age ≥18 years. Diffuse large B cell lymphoma is rare in participants \
Source: ClinicalTrials.gov (NCT07654426). StuddyBuddy aggregates publicly available trial information.
